Table 1 Baseline characteristics of involved studies
Study | Center | Study year | Age | Gender (M/F) | pTNM staging (I+II/III+IV) | Tumor differentiation (well moderate/poor) | Size of primary tumor, cm | Lymph node metastases | Mass-forming type | CA19-9 (U/ml) | CEA | Blood transfusion | Adjuvant chemotherapy | Quality score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bartsch, 2020 [20] | University Medical Center of the Johannes Gutenberg-University Mainz, Germany | 2008-2018 | 64.2 (32.3-84.4) | 73/77 | 60/63 | NA | NA | 63 | Â NA | NA | NA | NA | NA | 8 |
Cho, 2010 [21] | National Cancer Center, Korea | 2001-2007 | 61.4 (27-82) | 41/22 | NA | 28/32 | 6.4 (1.1-19) | 32 | 45/18 | 75.6 (5.0-7590.0) | NA | 6 | 8 | 8 |
Farges, 2011 [22] | Multicenter, European | 1998-2008 | NA | 108/104 | 134/78 | NA | 7.3 | 0 | 212/0 | NA | NA | NA | 40 | 7 |
Liu, 2021 [23] | Multicenter, China | 20011-2017 | 58 (49–64) | 287/191 | 290/88 | 375/203 | 6.7 | 88 | 154/324 | NA | NA | 84 | 97 | 9 |
Ma, 2016 [9] | The University of Hong Kong, China | 1991-2013 | 61 (25–79) | 58/49 | 70/37 | 57/26 | 6 (1–17) | 14 | NA | NA | 2.4 (0.3–151) | 27 | NA | 8 |
Shimada, 2007 [24] | National Cancer Center Hospital, Japan | 1995-2004 | 65 | 32/25 | NA | NA | 5.2 | 19 | 57/0 | 126 | 3 | NA | NA | 7 |
Tamandl, 2008 [17] | Medical University of Vienna, Austria | 1994-2007 | 63.2 (33.2-85.8) | 29/45 | NA | NA | NA | 23 | NA | NA | NA | NA | 27 | 8 |
Watanabe,2020 [16] | Multicenter, Japan | 2000-2017 | NA | 388/247 | 231/383 | 546/113 | 4.3 (2.8-6.5) | 152 | 401/234 | NA | NA | NA | NA | 8 |
Zhang, 2017 [25] | Multicenter, worldwide | 1990-2016 | 59 (51-68) | 569/454 | 776/173 | 811/117 | 6.2 (3.6-9.5) | 461 | 817 | 63.2 (11.2-341.3) | 2.4 (1.3-4.6) | 354 | NA | 7 |
Zheng, 2018 [26] | Peking Union Medical College, China | 2007-2016 | 54.9 (33-76) | 45/25 | 38/32 | 3/30/31 | NA | 13 | NA | NA | NA | 12 | NA | 7 |
Zhu, 2021 [27] | Fudan University Shanghai Cancer Center, China | NA | 59 | 66/60 | 96/30 | 68/51/7 | 6.4 | 33 | 118/8 | 67.00 (14.45-335.73) | 2.71 (1.73-6.62) | NA | 43 | 8 |